Cocrystal Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
March 02 2021 - 7:00AM
Cocrystal Pharma, Inc. (Nasdaq: COCP),
(“Cocrystal” or the “Company”), a clinical-stage biotechnology
company discovering and developing novel antiviral therapeutics
that target the replication machinery of influenza viruses, the
SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces
that management will present a company overview and hold virtual
investor meetings at the H.C. Wainwright Global Life Sciences
Virtual Conference being held January 9-10, 2021.
The Cocrystal Pharma webcast presentation can be
accessed by registering for the H.C. Wainwright Global Life
Sciences Virtual Conference here. The webcast will be available on
the H.C. Wainwright Conference Portal beginning March 9, 2021 at
7:00 a.m. Eastern time through March 10, 2021 at 9:00 p.m. Eastern
time. The Company’s corporate presentation can be accessed from the
Investor Relations section of the Company website here.
About Cocrystal Pharma,
Inc.
Cocrystal Pharma, Inc. is a clinical-stage
biotechnology company discovering and developing novel antiviral
therapeutics that target the replication process of influenza
viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses
and noroviruses. Cocrystal employs unique structure-based
technologies and Nobel Prize-winning expertise to create first- and
best-in-class antiviral drugs. For further information about
Cocrystal, please visit www.cocrystalpharma.com.
Investor Contact:LHA Investor RelationsJody
Cain310-691-7100jcain@lhai.com
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Apr 2024 to May 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From May 2023 to May 2024